Cocrystal Pharma (NASDAQ:COCP – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02), FiscalAI reports. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.10 million.
Cocrystal Pharma Stock Down 0.2%
NASDAQ:COCP opened at $0.98 on Tuesday. The stock has a market cap of $18.83 million, a P/E ratio of -1.29 and a beta of 1.60. The business’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $1.10. Cocrystal Pharma has a twelve month low of $0.76 and a twelve month high of $2.03.
Wall Street Analysts Forecast Growth
COCP has been the topic of a number of analyst reports. Weiss Ratings lowered Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. HC Wainwright restated a “buy” rating on shares of Cocrystal Pharma in a research note on Friday, October 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cocrystal Pharma presently has an average rating of “Hold”.
Check Out Our Latest Stock Report on Cocrystal Pharma
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.
Read More
- Five stocks we like better than Cocrystal Pharma
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
